Search clinical trials for: Rosiglitazone Extended Release 8mg

Total 1086 results

University of British Columbia
Paladin Labs Inc.

Recruiting

Tacrolimus Associated Tremors in Liver Transplantation: Immediate-Release Versus Extended-Release Formulations (LCP-TAC)

Liver Transplantation | Neurotoxicity | Tremor | Tacrolimus | Immunosuppression

Canada
Chinese University of Hong Kong

Recruiting

GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD) (GAPP-SVD)

Cerebral Small Vessel Disease

Hong Kong
Eisai Inc.

Completed

Comparing the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD)

Symptomatic Gastroesophageal Reflux Disease (sGERD)

United States
UMC Utrecht

Completed

Extended Release Tacrolimus (Advagraf®) in Severe Adult Atopic Dermatitis Patients

Atopic Dermatitis

Netherlands
GlaxoSmithKline

Completed

Clinical Evaluation of Ropinirole PR/XR Tablets in Monotherapy for Parkinson's Disease (PD)

Parkinson Disease

Japan
The University of Texas Health Science Center,...
National Institute of Mental Health (NIMH)

Completed

Methylphenidate for Attention Deficit Hyperactivity Disorder and Autism in Children

Autism | Attention Deficit Disorder With Hyperactivity

United States
Brigham and Women's Hospital
National Institute on Drug Abuse (NIDA); Arthritis Foundation

Completed

Opioid Treatment for Chronic Low Back Pain and the Impact of Mood Symptoms

Depression | Anxiety | Degenerative Disc Disease | Chronic Low Back Pain

United States
Georgetown University

Terminated

Envarsus XR in African American Renal Transplant Recipients (EXR)

Renal Transplant Recipients

United States
University of Illinois at Chicago
Astellas Pharma US, Inc.

Completed

A Pharmacokinetic Analysis of Tacrolimus ER Dosing in Obese Kidney Transplant Recipients (Tacrolimus ER)

Kidney Transplantation

United States
Egalet Ltd

Completed

Safety and Tolerability of Egalet-002 in Patients With Moderate-to-Severe Chronic Noncancer Pain

Moderate-to-severe Chronic Noncancer Pain

United States
Mayo Clinic
National Heart, Lung, and Blood Institute (NHLBI)

Completed

The Effects of Decreasing the Lasix Dose on the Cardiorenal System (Aim1)

Heart Failure | Kidney Dysfunction

United States
Chang Gung Memorial Hospital
AstraZeneca

Completed

Quetiapine Augmentation for Primary Anxiety Disorder or Mood Disorders With Co-morbid Anxiety Symptoms

Primary Anxiety Disorders | Mood Disorders With Comorbid Anxiety Symptoms

Taiwan
Mylan Pharmaceuticals Inc

Completed

Food Study of Oxybutynin Chloride Extended-release Tablets 5 mg and Ditropan XL® Tablets 5 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Propranolol Hydrochloride Extended-Release Capsules 160 mg and Inderal® LA Capsules 160 mg

Healthy

United States
Alkermes, Inc.

Completed

ALK21-014: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) After Enforced Abstinence

Alcohol Dependence
Ironshore Pharmaceuticals and Development, Inc

Completed

A Study of Delayed and Extended Release Formulation of Dextroamphetamine Sulfate (HLD100) in Children With ADHD (HLD100-103)

Attention-Deficit Hyperactivity Disorder (ADHD)

United States
Astellas Pharma Inc

Completed

Comparison of Plasma Concentration Changes Between Two Types of Tablets of FK949E Administration to Patients With Major Depressive Disorder

Major Depressive Disorder

Japan
Wake Forest University

Completed

Measurement of Kidney Blood Flow and Oxygen Levels by MRI

Chronic Kidney Disease

United States
Astellas Pharma Inc

Completed

Study to Evaluate the Effect of Food Intake on the Plasma Concentration Changes of Quetiapine After Oral Administration of FK949E in Healthy Volunteers

Healthy | Plasma Concentration Change of Quetiapine

Japan
Astellas Pharma Inc

Completed

Study to Evaluate Safety and Tolerability of FK949E in Elderly Patients With Major Depressive Disorder

Major Depressive Disorder Patients

Japan
Astellas Pharma Inc

Completed

Study to Evaluate Safety and Tolerability of FK949E in Patients With Major Depressive Disorder

Major Depressive Disorder Patients

Japan
Luye Pharma Group Ltd.

Completed

A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers

Parkinson Disease

United States
Alkermes, Inc.

Completed

ALK21-010: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol-dependent Adults

Alcoholism
Alkermes, Inc.

Terminated

ALK21-006EXT: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol- or Opioid-dependent Adults (Extension of Study ALK21-006 [NCT01218997])

Alcoholism | Opiate Dependence
Actavis Inc.

Completed

A Relative Bioavailability Study of Bupropion Sustained Release 150 mg Tablets Under Fasting Conditions

Healthy

United States
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

A Study to Evaluate the Efficacy of Tolterodine on Specific Symptoms in Adult Patients With Overactive Bladder.

Urinary Bladder, Overactive

United States
Merck Sharp & Dohme LLC

Terminated

A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118)

Dyslipidemia | Primary Hypercholesterolemia
Mylan Pharmaceuticals Inc

Completed

Food Study of Propranolol Hydrochloride Extended-Release Capsules 160 mg and Inderal® LA Capsules 160 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Oxybutynin Chloride Extended-release Tablets 5 mg and Ditropan XL® Tablets 5 mg

Healthy

United States
Alkermes, Inc.

Completed

ALK21-006: Long-Term Study of Medisorb® Naltrexone (VIVITROL®)

Alcoholism
Astellas Pharma Inc

Completed

Oral Multiple-dose Study in Patients With Major Depressive Disorder

Major Depressive Disorder

Japan
Alcobra Ltd.

Completed

A 6-week, Study of MG01CI Low Dose and High Dose Compared With Placebo in Adults and Adolescents With Fragile X Syndrome

Fragile X Syndrome

United States, Israel
AstraZeneca

Completed

Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended Release as Monotherapy in the Treatment of Patients With Bipolar Depression

Bipolar Depression

China
Ewha Womans University

Withdrawn

Effects of Seroquel XR on Sleep Architecture in Patients With Major Depressive Disorder

Major Depressive Disorder

Korea, Republic of
AstraZeneca

Completed

Evaluate the Pharmacokinetics of Quetiapine Fumarate in Chinese Schizophrenic Patients

Schizophrenia

China
Johnson & Johnson Pharmaceutical Research & Development...
Grünenthal GmbH

Completed

Study on the Safety and Effectiveness of Switching Between Two Forms of Tapentadol in Patients With Chronic Low Back Pain

Low Back Pain
Brigham and Women's Hospital
University of Utah

Not yet recruiting

Extended-release Buprenorphine as a Novel Low-dose Induction Strategy

Opioid Use Disorder
Purdue Pharma LP

Terminated

Efficacy and Safety of Hydromorphone Hydrochloride Extended-Release Compared to Placebo in Subjects With Persistent Pain

Chronic Non-Malignant Pain

United States
University of Minnesota
AstraZeneca; University of Iowa; Mclean Hospital

Completed

Seroquel Extended Release (XR) for the Management of Borderline Personality Disorder (BPD)

Borderline Personality Disorder

United States
Bangabandhu Sheikh Mujib Medical University, Dhaka...

Completed

Serum Creatinine Change / Renal Adverse Effect With Use of Non-steroidal Painkillers in Axial Spondyloarthritis Patients

Axial Spondyloarthritis
Actavis Inc.

Completed

A Relative Bioavailability Study of Propranolol HCl 160 mg Tablets Under Non-fasting Conditions

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Food Study of Divalproex Sodium Extended-Release Tablets 500 mg to Depakote ER® Tablets 500 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Single-Dose Fed Bioequivalence Study of Nisoldipine Extended-Release Tablets (40 mg; Mylan) and Sular® Extended-Release Tablets (40 mg; First Horizon) in Healthy Volunteers

Healthy

United States
Max Zeller Soehne AG

Completed

Pilot Pharmacokinetic Study of a Prolonged-release Formulation of St. John's Wort Extract Ze 117

Healthy

Germany
University at Buffalo
AstraZeneca

Terminated

GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes (1981)

Kidney Diseases | Type2 Diabetes

United States
Applied Science & Performance Institute

Recruiting

Acute Effects of PLT Health Solutions zümXR Extended-Release Caffeine

Cognitive Change | Mood | Caffeine | Mood Change

United States
The Methodist Hospital Research Institute
Veloxis Pharmaceuticals

Withdrawn

Evaluation of Anti-rejection Drug, Tacrolimus, in African-Americans With Kidney Transplant

Acute Rejection of Renal Transplant | Kidney Disease, End-Stage | Donor Specific Antibodies
Collaborative Care Initiative, LLC
Dauten Family Center for Bipolar Treatment Innovation, Massachusetts Gen...

Unknown

Comparison of Two Forms of Oxcarbazepine for the Treatment of Bipolar Depression

Bipolar Depression | Treatment Effectiveness | Measure-based Guidance

United States
Abbott

Completed

Comparative Study of 5 Days of M02-472 Clarithromycin Extended-Release Tablets to 7 Days of Clarithromycin Immediate-Release Tablets for the Treatment of Exacerbation of Chronic Bronchitis

Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB).

United States, Canada, Puerto Rico
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Alprazolam Extended-Release Tablets 3 mg to Xanax XR® Tablets 3 mg

Healthy

United States

3

Subscribe